AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7686471 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ethanol (HD)
Number of subjects: 42
Study 2881499 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 120
Study 2881499 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 120
Study 2881499 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Number of subjects: 120
Study 2881499 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 120
Study 29886915 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naloxone infusion (0.5 μg/kg/h)
Number of subjects: 84
Study 29886915 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose naloxone infusion (2.5 μg/kg/h)
Number of subjects: 84
Study 28049376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoneuroablation
Number of subjects: 207
Study 26364275 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine A (0.4 mg)
Number of subjects: 14
Study 26364275 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine A (0.8 mg)
Number of subjects: 14
Study 26364275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 24159353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract (2g per day in 2 POMx pills)
Number of subjects: 0
Study 24159353 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pills containing no pomegranate ingredients)
Number of subjects: 0
Study 21245872 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 12
Study 21245872 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 12
Study 21245872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18055508 — intervention group
Group type: EXPERIMENTAL
Intervention: One drink of red wine
Number of subjects: 13
Study 18055508 — intervention group
Group type: EXPERIMENTAL
Intervention: Two drinks of red wine
Number of subjects: 13
Study 18055508 — intervention group
Group type: EXPERIMENTAL
Intervention: One drink of ethanol
Number of subjects: 13
Study 18055508 — intervention group
Group type: EXPERIMENTAL
Intervention: Two drinks of ethanol
Number of subjects: 13
Study 16418628 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft Group (37 patients)
Number of subjects: 76
Study 16418628 — intervention group
Group type: COMPARATOR
Intervention: No Graft Group (39 patients)
Number of subjects: 76
Study 12564608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibenadet (500 microg)
Number of subjects: 2000
Study 12564608 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pressurized metered-dose inhaler)
Number of subjects: 2000
Study 10333886 — intervention group
Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy
Number of subjects: 15
Study 10333886 — intervention group
Group type: COMPARATOR
Intervention: Mandibular advancement (control)
Number of subjects: 15
Study 8767564 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (priming technique)
Number of subjects: 80
Study 8767564 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (priming technique)
Number of subjects: 80
Study 8767564 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (bolus method)
Number of subjects: 80
Study 8767564 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (bolus method)
Number of subjects: 80
Study 1888248 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (sustained release) 60 to 180 mg twice a day
Number of subjects: 242
Study 1888248 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 to 100 mg once a day
Number of subjects: 242
Study 1888248 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 to 20 mg once a day
Number of subjects: 242
Study 1888248 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 242
Study 1888248 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 242
Study 1888248 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 242
Study 1888248 — intervention group
Group type: EXPERIMENTAL
Intervention: All three treatments
Number of subjects: 242
Study 10255738 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (self-teaching booklet)
Number of subjects: 0
Study 10255738 — intervention group
Group type: EXPERIMENTAL
Intervention: VA education participants
Number of subjects: 0
Study 10255738 — intervention group
Group type: COMPARATOR
Intervention: Public health education group
Number of subjects: 0
Study 10255738 — intervention group
Group type: COMPARATOR
Intervention: Combined VA and public health education group
Number of subjects: 0
Study 10255738 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-teaching booklet alone
Number of subjects: 0
Study 31736433 — intervention group
Group type: EXPERIMENTAL
Intervention: U-Net deep learning model for tumor segmentation
Number of subjects: 502
Study 28880931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac output goal directed therapy (GDT) algorithm
Number of subjects: 52
Study 28880931 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 52
Study 25471599 — intervention group
Group type: EXPERIMENTAL
Intervention: WHEY (whey protein solution)
Number of subjects: 9
Study 25471599 — intervention group
Group type: EXPERIMENTAL
Intervention: GEL (leucine-enriched whey protein gel)
Number of subjects: 9
Study 25471599 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO (fasted state)
Number of subjects: 9
Study 23886255 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 55
Study 23886255 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 55
Study 21823549 — intervention group
Group type: COMPARATOR
Intervention: OM‐ER 15 mg
Number of subjects: 35
Study 21823549 — intervention group
Group type: COMPARATOR
Intervention: OM‐ER 30 mg
Number of subjects: 35
Study 21823549 — intervention group
Group type: EXPERIMENTAL
Intervention: OC‐CR 30 mg
Number of subjects: 35
Study 21823549 — intervention group
Group type: EXPERIMENTAL
Intervention: OC‐CR 60 mg
Number of subjects: 35
Study 21823549 — intervention group
Group type: COMPARATOR
Intervention: OM‐ER
Number of subjects: 35
Study 21823549 — intervention group
Group type: EXPERIMENTAL
Intervention: OC‐CR
Number of subjects: 35
Study 19854420 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk extension endurance
Number of subjects: 70
Study 19854420 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg press strength
Number of subjects: 70
Study 19854420 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk extension strength
Number of subjects: 70
Study 17181373 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifamycin-based antituberculosis therapy
Number of subjects: 0
Study 17181373 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 0
Study 17181373 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (alternative rifamycin)
Number of subjects: 0
Study 17181373 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin-based regimens
Number of subjects: 0
Study 17181373 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART regimens containing nevirapine or efavirenz
Number of subjects: 0
Study 17181373 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of HAART initiation after antituberculosis therapy
Number of subjects: 0
Study 14688377 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic NK cells
Number of subjects: 0
Study 14688377 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro assay and in vivo mouse model with human NK cells
Number of subjects: 0
Study 14688377 — intervention group
Group type: COMPARATOR
Intervention: Perugia donor-recipient KIR ligand-ligand mismatch model
Number of subjects: 0
Study 14688377 — intervention group
Group type: COMPARATOR
Intervention: Natural cytotoxicity model
Number of subjects: 0
Study 12221212 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition (Gln-enriched EN)
Number of subjects: 55
Study 12221212 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous control enteral nutrition (control EN)
Number of subjects: 55
Study 12221212 — intervention group
Group type: COMPARATOR
Intervention: Both trauma patient groups (glutamine and control)
Number of subjects: 55
Study 12221212 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine group
Number of subjects: 55
Study 12221212 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 10388372 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive resin (Scotchbond Multi‐Purpose Plus)
Number of subjects: 20
Study 10388372 — intervention group
Group type: COMPARATOR
Intervention: Copal varnish (Plastodent)
Number of subjects: 20
Study 7790500 — intervention group
Group type: EXPERIMENTAL
Intervention: Goretex Pantaloon cast liner
Number of subjects: 72
Study 7790500 — intervention group
Group type: COMPARATOR
Intervention: Standard cast without Goretex liner
Number of subjects: 72
Study 2112165 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical therapy with 2% mupirocin
Number of subjects: 153
Study 2112165 — intervention group
Group type: COMPARATOR
Intervention: Oral erythromycin
Number of subjects: 153
Study 113829 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-flupenthixol
Number of subjects: 0
Study 113829 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-flupenthixol
Number of subjects: 0
Study 113829 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorpromazine
Number of subjects: 0
Study 113829 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 6416510 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (insulin A)
Number of subjects: 14
Study 6416510 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin (insulin B)
Number of subjects: 14
Study 31216051 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of repaglinide and clopidogrel
Number of subjects: 0
Study 31216051 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide alone
Number of subjects: 0
Study 31216051 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide and clopidogrel
Number of subjects: 0
Study 31216051 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide and aspirin (without clopidogrel use)
Number of subjects: 0
Study 28654557 — intervention group
Group type: EXPERIMENTAL
Intervention: GMI+tDCS
Number of subjects: 22
Study 28654557 — intervention group
Group type: COMPARATOR
Intervention: GMI+sham tDCS
Number of subjects: 22
Study 27240549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime administered to mothers 15-60 minutes before Caesarean section
Number of subjects: 22
Study 23726831 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 151
Study 23726831 — intervention group
Group type: COMPARATOR
Intervention: Ferguson's with Electrocautery (FEH)
Number of subjects: 151
Study 23726831 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 151
Study 22963984 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA-LDL in circulating immune complexes (IC)
Number of subjects: 907
Study 22963984 — intervention group
Group type: EXPERIMENTAL
Intervention: oxLDL in circulating immune complexes (IC)
Number of subjects: 907
Study 22963984 — intervention group
Group type: EXPERIMENTAL
Intervention: AGE-LDL in circulating immune complexes (IC)
Number of subjects: 907
Study 20096821 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian diathermy (LOD)
Number of subjects: 50
Study 20096821 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) plus metformin
Number of subjects: 50
Study 18606054 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 16163743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by mental health professional for treatment of depression
Number of subjects: 0
Study 12415443 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline/dextran solution (HSS group, n=13)
Number of subjects: 29
Study 9915292 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based dialysis solution
Number of subjects: 0
Study 7587846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (multiple daily injections of insulin and glipizide)
Number of subjects: 153
Study 7587846 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin treatment (one morning injection per day)
Number of subjects: 153
Study 7587846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (stepped approach to insulin therapy)
Number of subjects: 153
Study 7587846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 153
Study 2341068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single daily dose)
Number of subjects: 40
Study 2341068 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin and Gentamicin (combined therapy every 8 hours)
Number of subjects: 40
Study 7017488 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncaspin (1.2 g suppositories, twice a day for 14 days)
Number of subjects: 30
Study 7017488 — intervention group
Group type: COMPARATOR
Intervention: Dimethylaminophenazone guaiacolglycolate (commercial form, twice a day for 14 days)
Number of subjects: 30
Study 31094806 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam IV (5-60 mg)
Number of subjects: 486
Study 31094806 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.15 mg/kg)
Number of subjects: 486
Study 31094806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study 27882910 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii-therapy
Number of subjects: 32
Study 27882910 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (SPT)
Number of subjects: 32
Study 24917588 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive taping (Group A)
Number of subjects: 70
Study 24917588 — intervention group
Group type: COMPARATOR
Intervention: Daily muscle manual stretching, passive articular mobilization, and palmar splint (Group B)
Number of subjects: 70
Study 24126211 — intervention group
Group type: EXPERIMENTAL
Intervention: HAC1 vaccine (90 μg non-adjuvanted)
Number of subjects: 80
Study 24126211 — intervention group
Group type: EXPERIMENTAL
Intervention: HAC1 vaccine (15 μg and 45 μg)
Number of subjects: 80
Study 24126211 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study 24126211 — intervention group
Group type: COMPARATOR
Intervention: Approved monovalent H1N1 vaccine
Number of subjects: 80
Study 22771827 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus sorafenib (gemcitabine 1000 mg/m² i.v., weekly seven times followed by 1 rest week, then weekly three times every 4 weeks plus sorafenib 200 mg, two tablets p.o., twice daily continuously)
Number of subjects: 104
Study 22771827 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus placebo (gemcitabine 1000 mg/m² i.v., weekly seven times followed by 1 rest week, then weekly three times every 4 weeks plus placebo, two tablets p.o., twice daily continuously)
Number of subjects: 104
Study 19915774 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular surgery
Number of subjects: 0
Study 19915774 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study 17481800 — intervention group
Group type: EXPERIMENTAL
Intervention: Etilefrine
Number of subjects: 50
Study 17481800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15361287 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg synthetic allitridum every day and 100 microg selenium every other day for one month each year from November 1989 to December 1991.
Number of subjects: 5026
Study 15361287 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules containing corn oid.
Number of subjects: 5026
Study 11550729 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session Preparing for the Drug Free Years Program
Number of subjects: 667
Study 11550729 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-session Iowa Strengthening Families Program
Number of subjects: 667
Study 11550729 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact control condition
Number of subjects: 667
Study 9786103 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 150 mg/day plus Nortriptyline 50 mg/day
Number of subjects: 30
Study 9786103 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine 150 mg/day plus Placebo
Number of subjects: 30
Study 8187231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran sulfate immobilized on cellulose in the Liposorber LA-15 system
Number of subjects: 64
Study 8187231 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 64
Study 3555942 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (propranolol)
Number of subjects: 0
Study 3555942 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 31563497 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL 2.0 risk score (full eight-tier model)
Number of subjects: 1011
Study 31563497 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL 2.0 risk score (three-category model)
Number of subjects: 1011
Study 31563497 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL 2.0 risk score (incident cases only)
Number of subjects: 1011
Study 30817099 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 or 70 mg
Number of subjects: 745
Study 30817099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study 28277486 — intervention group
Group type: EXPERIMENTAL
Intervention: Kriens intravelar veloplasty (IVV)
Number of subjects: 42
Study 28277486 — intervention group
Group type: COMPARATOR
Intervention: non-IVV 2-flap repair
Number of subjects: 42
Study 25015519 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain placement in the subhepatic space (Group A)
Number of subjects: 160
Study 25015519 — intervention group
Group type: COMPARATOR
Intervention: No drainage (Group B)
Number of subjects: 160
Study 23621831 — intervention group
Group type: EXPERIMENTAL
Intervention: En bloc stapler ligation of the renal hilum (Group A)
Number of subjects: 70
Study 23621831 — intervention group
Group type: COMPARATOR
Intervention: Separate ligation method (Group B)
Number of subjects: 70
Study 23621831 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 70
Study 21566299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 30 mg daily with main meal, titrated monthly
Number of subjects: 27
Study 21566299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 90 mg once weekly and 120 mg midweek with main meal, titrated monthly
Number of subjects: 27
Study 19514814 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity laser irradiation (LILI) at 780 nm; 7.5 mW; 292 Hz modulation for 30 seconds
Number of subjects: 123
Study 16767577 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoscopy and structure enhancement
Number of subjects: 292
Study 16767577 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy (Control)
Number of subjects: 292
Study 14732316 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V (q8 hourly for 10 days)
Number of subjects: 265
Study 14732316 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (q12 hourly for 10 days)
Number of subjects: 265
Study 14732316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (q12 hourly for 5 days)
Number of subjects: 265
Study 11033392 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser photoastigmatic refractive keratectomy (PARK)
Number of subjects: 56
Study 9200197 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid etch technique (AE)
Number of subjects: 85
Study 9200197 — intervention group
Group type: COMPARATOR
Intervention: Air abrasion with no acid etch (KCP‐1000)
Number of subjects: 85
Study 8259810 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health nurse intervention promoting influenza immunization
Number of subjects: 0
Study 8259810 — intervention group
Group type: COMPARATOR
Intervention: Public health nurse intervention promoting safety measures
Number of subjects: 0
Study 3935127 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium crompromate (SCP)
Number of subjects: 9
Study 3935127 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 9
Study 3935127 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 9
Study 31249235 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for proteinuria using dipstick tests and protein-to-creatinine ratio
Number of subjects: 485
Study 30024530 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 70
Study 30024530 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 70
Study 26114464 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Legends program (life review writing + intergenerational exchange)
Number of subjects: 0
Study 26114464 — intervention group
Group type: COMPARATOR
Intervention: Life review writing alone
Number of subjects: 0
Study 24081972 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 1034
Study 24081972 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1034
Study 21246521 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant procarbazine, lomustine, and vincristine (PCV)
Number of subjects: 92
Study 21246521 — intervention group
Group type: EXPERIMENTAL
Intervention: INA expression
Number of subjects: 92
Study 19200833 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16997367 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge that gesture and speech were intentionally coupled (produced by the same communicator)
Number of subjects: 35
Study 16997367 — intervention group
Group type: COMPARATOR
Intervention: Knowledge that gesture and speech were not intentionally coupled (produced by different communicators)
Number of subjects: 35
Study 15042673 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (PSA testing every 2 years for 8 years)
Number of subjects: 10000
Study 15042673 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 10000